Nintedanib Slows Decline in RA-Associated Interstitial Lung Disease

email article
Patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) had slower rates of decline in lung function over 1 year when treated with nintedanib (Ofev), an intracellular inhibitor of tyrosine kinases, according to a post-hoc analysis from a larger trial known as INBUILD.
Among patients with RA-ILD randomized to nintedanib, the rate of decline in forced vital capacity (FVC) at 52 weeks was -82.6 mL/year compared with a rate of -199.3 mL/year among those receiving placebo, which represented a difference of 116.7 mL/year (95% CI 7.4-226.1,
P=0.037), reported Clive Kelly, MD, of Newcastle University in Newcastle upon Tyne in England, at the European League Against Rheumatism virtual congress.

Related Keywords

Clive Kelly ,Nancy Walsh ,Regina College In Newport ,Newcastle University In Upon Tyne ,Peuropean League Against Rheumatism ,Newcastle University ,Salve Regina College ,League Against ,Nintedanib ,Interstitial Lung Disease ,Traction Bronchiectasis ,Kcrp ,C Reactive Protein ,கிளைவ் கெல்லி ,நான்சி வால்ஷ் ,ரெஜினா கல்லூரி இல் நியூபோர்ட் ,நியூகேஸில் பல்கலைக்கழகம் இல் மீது டைன் ,ஐரோப்பிய லீக் எதிராக வாத நோய் ,நியூகேஸில் பல்கலைக்கழகம் ,சால்வ் ரெஜினா கல்லூரி ,லீக் எதிராக ,இடையிடையே நுரையீரல் நோய் ,சிற்ப ,